Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
CaDAnCe-101
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- NCT05006716 ↗
- Recruiting
- BeOne Medicines
- Standard
We haven't built an HCP commentary report on CaDAnCe-101 (tacabrutideg (BGB-16673) in B-cell malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CaDAnCe-101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 13 | |
| X threads | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma; Waldenström Macroglobulinemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Richter Transformation
- Interventions
- Tacabrutideg
- Arms
- Part 1a (Monotherapy Dose Escalation) · Experimental
- Part 1b (Monotherapy Safety Expansion) · Experimental
- Part 1c (Additional Monotherapy Safety Expansion) · Experimental
- Part 1d (Additional Monotherapy Safety Expansion in R/R CLL/SLL) · Experimental
- Part 1e (Japan-only Cohort) · Experimental
- Part 1f (Additional Monotherapy Safety Expansion in BTKi Naive B-Cell Malignancies) · Experimental
- Phase 2 (Monotherapy Expansion) · Experimental
- Enrollment
- 689 (estimated)
- Primary outcomes
- Phase 1: Number of Participants with Adverse Events (AEs)
- Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Tacabrutideg
- Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutideg
- Phase 2: Overall response rate (ORR)
- Sponsor
- BeOne Medicines
- Start
- Sep 13, 2021
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05006716 · updated Oct 5, 2026